HPS4 biogenesis of lysosomal organelles complex 3 subunit 2Genealiases: BLOC3S2 · LE
Q-omics provides the consensus-scored HPS4 profile across patient tissues and cancer cell-line models. HPS4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, HPS4 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, HPS4 RNA expression shows 21,023 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, HNSC, and ACC as cancer lineages where HPS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HPS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HPS4 survival associations across molecular data types. HPS4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HPS4 RNA expression–survival associations across cancer types. High HPS4 expression shows unfavorable associations in ACC and LIHC, but favorable associations in BRCA, ESCA, READ and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for HPS4 RNA expression.
This table summarizes HPS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HPS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HPS4 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, COAD and BLCA. The HNSC box plot shows higher HPS4 RNA expression in tumor versus normal tissue (log2 FC = +0.808, t-test p < 0.001).
This table shows molecular features associated with HPS4 in patient tissues and cancer cell lines. In patient samples, HPS4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HPS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
